Get the latest news and updates
Dr. Thompson is on the ECOG-ACRIN Myeloma and Lymphoma Core committees. He is currently on the NCI Lymphoma Steering Committee. At ASCO he was a member of the Cancer Research Committee. Dr. Thompson was Chair (2016-2017) of the ASCO Research Community Forum. He was Chair (2016-2017) of the ASCO Education Committee. Medical Director of the Early Phase Cancer Research Program. Co-PI of the Aurora NCI Community Oncology Research Program (NCORP) and is co-Director of Aurora’s Oncology Precision Medicine program. He received his BS in Molecular Biology - Honors from the University of Wisconsin - Madison, his MD at Mayo Medical School, and PhD in Molecular Pharmacology and Experimental Therapeutics from the Mayo Graduate School in the pharmacogenetics laboratory of Richard Weinshilboum, MD. He completed his Internal Medicine Residency at the Mayo Clinic College of Medicine. His Hematology/Oncology Fellowship was at the MD Anderson Cancer Center.
The Molecular Tumor Board (MTB) was mostly established to facilitate the incorporation of molecular diagnostics into the consideration of appropriate therapies for patients with late stage cancer. Initially, much of the deliberation was focused on understanding the results of such testing, as reporting of results was limited in scope and frequently understandable only to cutting edge experts in the field. Improved, but still not perfect, reporting now exists, so discussion has shifted to prognostic and therapeutic considerations. That said, the collective experience with rare mutations and off label therapies is still such that collective wisdom is necessary. This brings up the issue of how MTBs collect, share, and preserve data within a specific MTB, and perhaps more importantly, how it might be shared amongst MTBs and beyond. While initial activity related to MTBs resided almost exclusively in large academic, and select community, medical centers, there is now significant effort in the commercial setting as well, with a number of intriguing efforts presently underway. Important and evolving issues, such as defining which patients are most likely to benefit from the efforts of a MTB, Virtual MTBs, and the generation of Real World Evidence, will be discussed.